{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-116864","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2024-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.249168+00:00","generated_at":"2026-05-30T10:24:21.772588+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Precision BioSciences reports ~$121M cash, gets first CTA approval for PBGENE-HBV in Moldova","bullets":["Expected cash, cash equivalents, and restricted cash of ~$121M as of Sept 30, 2024 (preliminary, unaudited).","Received CTA approval in Moldova for PBGENE-HBV, a first-in-human in vivo gene editing study for chronic hepatitis B.","PBGENE-HBV targets and eliminates cccDNA and inactivates integrated HBV DNA, aiming for functional cure.","Company to host investor event on Nov 15, 2024 prior to AASLD meeting to share preclinical safety package and Phase 1 trial details.","Additional global CTA and IND submissions underway to accelerate patient enrollment across multiple sites."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-116864","json":"https://secwatch.observer/filing/0000950170-24-116864.json","markdown":"https://secwatch.observer/filing/0000950170-24-116864.md","text":"https://secwatch.observer/filing/0000950170-24-116864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024116864/0000950170-24-116864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024116864/dtil-20241024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:24:21.772588+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}